Neal Freiman

speaker

14,692 appearances 180 recordings 1 series first heard Nov 2024 last heard 11 Jun

Neal Freiman’s voice in public audio — every appearance, attributed to the second.

Trend

recordings per month · last 12 months

Recordings per month over the last 12 months — 42 in all, peaking in Feb 2026 with 9.

Appearances

newest first · ▶ plays the moment

Morning Brew Daily · The Tim Cook Era is Ending & Pancreatic Cancer Breakthrough? · 21 Apr 2026 podcast

which is affiliated with Blue Origin a little bit, has just a couple hundred.

So SpaceX is absolutely dominating this industry.

And Blue Origin has this new rocket, which this failed satellite went up on, which is New Glenn.

And it's attempting to compete with the Falcon 9 booster.

The Falcon 9 booster from SpaceX has just such a head start.

It is the workhorse.

It is so reliable.

SpaceX can recycle a Falcon 9 booster for reflight in just nine days.

And it can launch this thing five or more times in one week.

This is just a science for SpaceX, and Blue Origin is still getting its space legs.

Moving on, at a major cancer conference in San Diego yesterday, researchers presented what may end up being a watershed moment for pancreatic cancer treatment.

Of the 16 patients who were given a personalized mRNA vaccine in 2020, eight showed a significant immune response, and seven are alive today, six years after the trial began.

If that doesn't sound like an incredible result, just remember that pancreatic cancer is one of the deadliest out there.

Most patients live just a few months longer, while less than 13% of people live for more than five years after being diagnosed.

And since there's no routine screening for pancreatic cancer, you can only really tell when symptoms show up, often at an advanced stage.

The five-year survival rate for stage four pancreatic cancer is 3%.

The results are another very promising development for applying mRNA technology, which was harnessed by some drug makers to create effective COVID vaccines.

In this case, BioNTech and Genentech, the two companies behind the pancreatic cancer vaccine, used genetic material taken from individual tumors to create a unique vaccine personalized for each patient.

Toby, this is a very small trial, just 16 patients, so it's irresponsible to draw sweeping conclusions before more studies are done.

Showing 1261–1280 of 14,692 · page 64 of 735